Treat-to-target approach for CVD risk factors decreased atherosclerosis in RA patients
The addition of the two latest treatment regimens for hepatitis C essentially closes the circle on treatment of this disease. Don’t shorten therapy for older, sicker cellulitis patients, apixaban and rivaroxaban reversal agent gets FDA approval, and do black women pay a price for hair care products?
Listen to the MDedge Daily News podcast for all the details on today’s top news.
We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.